Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

How And Why Genzyme And Alnylam Expanded Their Alliance

Executive Summary

Genzyme’s decision to deepen its alliance with Alnylam plays to the strategic needs of both parties and to their complementary strengths. The agreement also was helped by the companies’ physical proximity and by a high-level conversation between Maraganore and Viehbacher at a critical juncture.

You may also be interested in...



Regeneron Looks To Use CRISPR Inside/Outside The Liver With Intellia Pact

Under partnership with Intellia, Regeneron will use gene-editing technology to develop novel therapeutics against up to 10 targets, and will make a $50m equity investment in the biotech.

Alnylam Advancing From Platform Buzz To Late-Stage Clinical Work

RNAi pioneer is getting closer to market with NDA filing in amyloidosis expected in 2017, but ample competition is coming along, albeit far behind.

Earnings Updates, In Brief: Momenta, Acorda, Sangamo, Lundbeck, Actelion, Alnylam, Seattle Genetics

Year-end earnings reports from the biotech crowd show movement in the biosimilar field, faith in RNAi, high value for rare disease approaches and strategies to defend and grow primary assets.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS055859

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel